EUVIMEDEUVIMED entdecken
Crossref

Balancing Effective Treatments With Potential Threats: The Impact of Biologic Agent Use on Tuberculosis Development in Children With Chronic Inflammatory Disorders

Ayse Hitay Telefon iD, Merve Kilic Cil iD, Gulsum Sonmez iD, Elif Afat Turgut iD, Tugba Kandemir Gulmez iD, Didem Gulcu Taskin iD, Sevinc Garip iD, Rabia Miray Kisla Ekinci iD, Umit Celik iD

International Journal of Rheumatic Diseases · 2025

DOI: 10.1111/1756-185x.70145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Ayse Hitay Telefon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Infectious Diseases, Ministry of Health Adana City Training & Research Hospital: TC Saglik Bakanligi Adana Sehir Egitim ve Ar…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Tuberculosis, Biological Products, Rheumatic Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We aimed to investigate the frequency and clinical characteristics of tuberculosis in pediatric patients receiving both anti‐TNF‐alpha and other biological agents. Materials and Methods The data of 270 patients who used biological agents due to rheumatologic diseases and inflammatory bowel disease (IBD) and were followed between January 2021 and October 2023 were retrospectively collected from their files.

Results

Of the patients, 138(51.1%) were female, 132(48.9%) were male. The mean age at diagnosis was 107 months (min 8–max 215 months). Patients were most commonly followed for juvenile idiopathic arthritis (JIA) (191 patients, 70.7%), followed by other autoinflammatory diseases (49 patients) and IBD (26 patients, 9.6%). Treatments included adalimumab (97 patients, 35.9%), etanercept (85 patients, 31.5%), canakinumab (33 patients, 12.2%), tocilizumab (31 patients, 11.5%), infliximab (16 patients, 5.9%), anakinra (5 patients, 1.9%), tofacitinib (2 patients, 0.7%), and rituximab (1 patient, 0.4%). During follow‐up, latent tuberculosis infection (LTBI) developed in 5 (1.9%) patients. Three of these patients had JIA (using adalimumab, etanercept and tocilizumab), one had Familial Mediterranean Fever (using canakinumab), and one had IBD (using adalimumab). The mean duration of biological agent treatment until LTBI development was 14.6 months (min 6–max 29 months). Tuberculosis disease was diagnosed in two patients. Both were patients followed up due to IBD. One of the patients was diagnosed with miliary tuberculosis after infliximab treatment, while the other was followed for tuberculosis lymphadenitis after adalimumab treatment. Quadruple anti‐tuberculosis therapy was initiated for the patients.

Conclusion

The use of biological agents has revolutionized the course of chronic inflammatory diseases in childhood. However, in these patients, monitoring for tuberculosis risk is crucial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesTuberculosisBiological ProductsRheumatic DiseasesBiological FactorsAntirheumatic AgentsHumansFemaleMaleChildRetrospective StudiesChild, PreschoolAdolescentArthritis, JuvenileTreatment Outcome

Stichwörter der Autor:innen

biologic agentsinflammatory bowel diseasepediatricsrheumatologytuberculosis

Substanzen

Biological ProductsBiological FactorsAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Pediatric Infectious Diseases, Ministry of Health Adana City Training & Research Hospital: TC Saglik Bakanligi Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Turkey.
  • Department of Pediatric Gastroenterology, Ministry of Health Adana City Training & Research Hospital: TC Saglik Bakanligi Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Turkey.
  • Department of Pediatric Rheumatology, Cukurova University Faculty of Medicine: Cukurova Universitesi Tip Fakultesi, Adana, Turkey.

ORCID-Profile: Ayse Hitay Telefon, Merve Kilic Cil, Gulsum Sonmez, Elif Afat Turgut, Tugba Kandemir Gulmez, Didem Gulcu Taskin, Sevinc Garip, Rabia Miray Kisla Ekinci, Umit Celik

Zitieren

APA

Telefon, A. H., Cil, M. K., Sonmez, G., Turgut, E. A., Gulmez, T. K., Taskin, D. G., Garip, S., Ekinci, R. M. K., & Celik, U. (2025). Balancing Effective Treatments With Potential Threats: The Impact of Biologic Agent Use on Tuberculosis Development in Children With Chronic Inflammatory Disorders. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70145

Vancouver

Telefon AH, Cil MK, Sonmez G, Turgut EA, Gulmez TK, Taskin DG, et al. Balancing Effective Treatments With Potential Threats: The Impact of Biologic Agent Use on Tuberculosis Development in Children With Chronic Inflammatory Disorders. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70145

BibTeX
@article{Telefon2025,
  author = {Telefon, Ayse Hitay and Cil, Merve Kilic and Sonmez, Gulsum and Turgut, Elif Afat and Gulmez, Tugba Kandemir and Taskin, Didem Gulcu and Garip, Sevinc and Ekinci, Rabia Miray Kisla and Celik, Umit},
  title = {Balancing Effective Treatments With Potential Threats: The Impact of Biologic Agent Use on Tuberculosis Development in Children With Chronic Inflammatory Disorders},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  doi = {10.1111/1756-185x.70145}
}
Kostenlos starten →